ArriVent Q2 2025 net loss $95.8M; firmonertinib PACC data positive; ADC ARR-217 dosed

ArriVent BioPharma, Inc.

2025-Q2 EPS reported -$2.78 vs consensus -$0.72 ▼ miss (-287.3%)

Cash and investments $254.5M at June 30, plus $81.1M raised in July 2025 public offering; runway extended to mid-2027.
Net loss $95.8M for H1 2025 vs. $39.3M in H1 2024; R&D expense $89.0M including $40M one-time upfront to Lepu BioPharma.
Positive interim Phase 1b data for firmonertinib in EGFR PACC mutant NSCLC; final data at WCLC September 2025.
First patient dosed in Phase 1 for ARR-217 (CDH17-targeted ADC) in gastrointestinal tumors by partner Lepu.
Top-line firmonertinib data from FURVENT Phase 3 for EGFR Exon20 insertion expected early 2026; PACC Phase 3 ALPACCA enrollment in 2H 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.